ClinicalTrials.gg
TerminatedNCT00387036Updated Jan 21, 2016Results posted

Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)

A Phase 2 interventional study of Fluticasone and Comparator: Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Termininated for business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
56th of 59
12 · median 95
Started
2006
with 4 others
Phase 2
10 of 59
none open now
Registered
7th of 59
by date

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 56th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 2, and was the 7th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 40 years and older
  • Clinical diagnosis of for greater than one year
  • History of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Other lung diseases (not including ), such as asthma
  • A condition that could interfere with your ability to perform exercise tests
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Other
    1

    Arm 1: drug, crossing over to Pbo comparator

    Drug: Fluticasone

  • Other
    2

    Arm 2: Pbo comparator, crossing over to drug

    Drug: Fluticasone · Drug: Comparator: Placebo

Interventions

  • fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.

  • DrugComparator: Placebo

    Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.

06

What researchers measure

Primary outcomes

  1. Standardized Dyspnea Score at Isotime During Exercise

    Difference in standardized dyspnea rating at isotime during constant load exercise in patients with COPD between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period. Isotime is the duration of the shortest exercise test on all treatment days (or the longest exercise time point common to all constant-load exercise tests). The standardized dyspnea score will be measured with the modified 10-point Borg Scale (0 \[Best\] - 10 \[Worst\] ).

    Time frame: 2 Weeks

Secondary outcomes

  1. Exercise Endurance Time

    Difference in exercise endurance time between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.

    Time frame: 2 Weeks

07

Results

Posted May 26, 2010

Participant flow

Patients were recruited from 1 center in Canada. Patient screening began 14-Dec-2006 and the first patient was randomized on 16-Feb-2007. Last patient last visit for the study was 31-Jul-2009.

2-Week First Intervention
Participant flow — 2-Week First Intervention
MilestoneFluticasone Propionate Then PlaceboPlacebo Then Fluticasone Propionate
Started66
Completed66
Not completed00
2-Week Placebo Washout
Participant flow — 2-Week Placebo Washout
MilestoneFluticasone Propionate Then PlaceboPlacebo Then Fluticasone Propionate
Started66
Completed66
Not completed00
2-Week Crossover Second Intervention
Participant flow — 2-Week Crossover Second Intervention
MilestoneFluticasone Propionate Then PlaceboPlacebo Then Fluticasone Propionate
Started66
Completed66
Not completed00

Outcome measures

PrimaryStandardized Dyspnea Score at Isotime During Exercise

Difference in standardized dyspnea rating at isotime during constant load exercise in patients with COPD between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period. Isotime is the duration of the shortest exercise test on all treatment days (or the longest exercise time point common to all constant-load exercise tests). The standardized dyspnea score will be measured with the modified 10-point Borg Scale (0 \[Best\] - 10 \[Worst\] ).

Time frame:
2 Weeks
Reported as:
Mean · Units on a Scale
Standardized Dyspnea Score at Isotime During Exercise
Units on a ScaleFluticasone PropionatePlacebo
Standardized Dyspnea Score at Isotime During Exercise3.58 ± 2.144.50 ± 2.18
Statistical analysis
  • Fluticasone Propionate vs Placebo · Mean difference (final values): -0.92 · 90% CI -1.59 to -0.25
SecondaryExercise Endurance Time

Difference in exercise endurance time between Fluticasone Propionate treatment and placebo treatment at the end of the treatment period.

Time frame:
2 Weeks
Reported as:
Mean · Minutes
Exercise Endurance Time
MinutesFluticasone PropionatePlacebo
Exercise Endurance Time12.92 ± 10.529.75 ± 6.93
Statistical analysis
  • Fluticasone Propionate vs Placebo · Mean difference (final values): 3.17 · 90% CI -0.28 to 6.61

Adverse events

Collected over Screening to 14 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate—0/12 (0%)5/12 (41.7%)
Placebo—0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventFluticasone PropionatePlacebo
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/122/12
Gastrooesophageal Reflux DiseaseGastrointestinal disorders1/120/12
Gastrointestinal InfectionInfections and infestations1/120/12
NasopharyngitisInfections and infestations1/120/12
PneumoniaInfections and infestations1/120/12
Viral InfectionInfections and infestations1/120/12
Tooth FractureInjury, poisoning and procedural complications1/120/12
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/121/12
Upper Respiratory Tract CongestionRespiratory, thoracic and mediastinal disorders0/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean67.9 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female4
Male8
Exercise endurance time at the beginning of Fluticasone Propionate
Exercise endurance time at the beginning of Fluticasone Propionate(Minutes)Entire Study Population
Mean9.67 ± 7.88
Exercise endurance time at the beginning of placebo treatment
Exercise endurance time at the beginning of placebo treatment(Minutes)Entire Study Population
Mean9.42 ± 6.73
Standardized Dyspnea Score at isotime at the beginning of Fluticasone
Standardized Dyspnea Score at isotime at the beginning of Fluticasone(Units on a Scale)Entire Study Population
Mean4.50 ± 1.87
Standardized Dyspnea Score at isotime at the beginning of placebo
Standardized Dyspnea Score at isotime at the beginning of placebo(Units on a Scale)Entire Study Population
Mean4.75 ± 2.13
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O'Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med. 2011 Dec;105(12):1836-45. doi: 10.1016/j.rmed.2011.08.021. Epub 2011 Sep 13. PubMed 21917440 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2006
First posted
Oct 12, 2006
Start
Dec 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
May 26, 2010
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00387036
Responsible party
Sponsor
First posted
Oct 12, 2006
Start date
Dec 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
May 26, 2010
Last update
Jan 21, 2016

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion